Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study
|
|
- Alexandra Norman
- 5 years ago
- Views:
Transcription
1 280 Journal of Pain and Symptom Management Vol. 20 No. 4 October 2000 Original Article Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study Carlo Dallocchio, MD, Carlo Buffa, MD, Paolo Mazzarello, MD, and Silvia Chiroli, MD Department of Neurology and Rehabilitative Medicine-S. Giacomo Hospital (C.D., C. B.), Novi Ligure; Biochemical and Evolutionist Genetic Institute, National Research Council (P.M.), Pavia; and Medical Division, Parke-Davis SpA, Milan, Italy (S.C.) Abstract The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in ful diabetic neuropathy. This was a 12-week, open-label, prospective, randomized trial. Twenty-five type-ii diabetic patients with attributed to diabetic neuropathy and a minimum of 2 on a intensity scale ranging from 0 (no ) to 4 (excruciating ) were randomized to receive either gabapentin, titrated from 1,200 mg/day to a maximum of 2,400 mg/day, or amitriptyline, titrated from 30 mg/day to a maximum of 90 mg/day. Both drugs were titrated over a 4-week period and maintained at the maximum tolerated dose for 8 weeks. The main outcome measures were weekly intensity and intensity, measured on two categorical scales. Thirteen patients received gabapentin and 12 received amitriptyline. All 25 patients completed the trial. Gabapentin produced greater reductions than amitriptyline (mean final s were 1.9 vs. 1.3 points below baseline s; P 0.026). Decreases in s also were in favor of gabapentin (1.8 vs. 0.9 points; P 0.004). Adverse events were more frequent in the amitriptyline group than in the gabapentin group: they were reported by 11/12 (92%) and 4/13 (31%) of patients, respectively (P 0.003). Side effects were the main limiting factor preventing dose escalation. Gabapentin produced greater improvements than amitriptyline in and associated with diabetic neuropathy. Additionally, gabapentin was better tolerated than amitriptyline. Further controlled trials are needed to confirm these preliminary results. J Pain Symptom Manage 2000;20: U.S. Cancer Pain Relief Committee, Key Words Gabapentin, amitriptyline, diabetic neuropathy,, Introduction Gabapentin (GBP) is an anticonvulsant whose efficacy has been recently demonstrated Address reprint requests to: Paolo Mazzarello, MD, Istituto di Genetica, Biochimica ed Evoluzionistica, CNR, Via Abbiategrasso 207, I Pavia, Italy. Accepted for publication: November 6, in a double-blind, placebo-controlled trial of treatment of ful diabetic neuropathy. 1 Classically, tricyclic antidepressant (TCA) agents have been considered the first-line therapy for ful diabetic neuropathy. 2 4 No studies have been published comparing efficacy and side effects of GBP vs. TCAs. The aim of this study was to perform a preliminary comparison of the efficacy and safety U.S. Cancer Pain Relief Committee, /00/$ see front matter Published by Elsevier, New York, New York PII S (00)
2 Vol. 20 No. 4 October 2000 GBP vs. AMI in Painful Diabetic Neuropathy 281 of GBP with a TCA, amitriptyline (AMI), in elderly patients with ful diabetic neuropathy. In this trial, AMI was chosen as the comparative drug because it is considered the gold standard in the treatment of diabetic neuropathy and its efficacy has been demonstrated in several clinical trials. 5 7 Other TCAs, such as desipramine, 8 imipramine, 9 and nortriptyline, 10 have been studied in diabetic neuropathy or other ful conditions. Some reviews indicate that AMI is the most effective TCA in the treatment of neuropathic and note that it is probably the least tolerated one due to side effects that are frequently dose limiting. 11,12 Methods This was an open-label pilot study with a 12- week. Patients were randomly allocated to therapy with either GBP or AMI. Patients eligible for inclusion were male or female, aged 60 years, with type-ii diabetes (stabilized glycemic values) and clinically relevant lower limb polyneuropathy with significant and s lasting at least 6 months. On examination, patients had to exhibit either absence of Achilles reflexes or reduction of vibration sensitivity. Eligible patients also had to obtain a intensity of at least 2 on a 4-point (0 4) categorical scale (0, no ; 1, mild ; 2, moderate ; 3, severe ; 4, excruciating ). Each patient was asked to rate the average experienced during the previous use of GBP or AMI; presence of renal, hepatic or cardiovascular insuffiency; diabetic neuropathy not meeting the above criteria; neuropathy of different etiology; and current/previous diagnosis of psychiatric disorder. The use of other adjuvant analgesics, such as other TCAs, mexiletine, carbamazepine, or other anticonvulsants, was forbidden throughout the study. In cases of previous administration of such drugs, they had to be discontinued at least 1 month prior to randomization. Benzodiazepines were allowed if their dose had been stable for at least 1 month before randomization and was kept unchanged throughout the study. GBP and AMI were administered as monotherapy, with a three-time daily dosing schedule. GBP was started at 400 mg/day and AMI was started at 10 mg/day. During the first week of study, the dosage was titrated in all patients up to 1,200 mg/day GBP or 30 mg/day AMI. Over the following 3 weeks, doses were further increased in an effort to reduce s to 1 or less. Titration up to a maximum of 2,400 mg/day GBP or 90 mg/day AMI was performed by weekly increments of 400 mg/day for GBP or 20 mg/day for AMI. However, in case of intolerable side effects, doses were increased up to the maximum tolerated dosage. Thereafter, through the last 8 weeks of study, doses were kept constant. The primary efficacy parameter was the at the last visit. A secondary efficacy parameter was the, measured on a 4-point categorical scale similar to the scale. Each patient was also asked to describe the quality of the perceived and to specify whether s were ful or just tingling sensations. Safety profiles of the drugs were compared by recording the occurrence of adverse events. The small size of data sets dictated that distribution-free methods should be used for the analyses since assumptions about the distribution of variables and homogeneity of variances could not be made. Two-tailed tests were used for the analyses with a significance level of P Gender (female/male) and antidiabetic therapy (oral antidiabetic agents or insulin) were compared in the two groups (GBP and AMI) by Fisher s exact test. The Mann-Whitney U-test for independent samples was used to compare the two groups for age, of diabetes, of and s (months), and baseline s of and. Within-group differences were compared with baseline values by using the Wilcoxon matched-pairs signed-ranks test. The Mann- Whitney U-test was applied to differences from baseline values to assess the effects of both treatments. Fisher s exact test was used to compare the frequencies of adverse events observed in the two treatment groups. Results A total of 25 patients were enrolled and all of them completed the trial. Thirteen individuals (seven males and six females) were treated with GBP at the mean dose of mg/ day, while 12 patients (four males and eight fe-
3 282 Dallocchio et al. Vol. 20 No. 4 October 2000 Patient no. Gender Age Diabetes Pain (months) Type of Table 1 Data for GBP-Treated Patients Type of Antidiabetic therapy Maximum dose (mg/day) Adverse events 1 F Burning Tingling Oral 1, Dizziness 2 F Cramping Tingling Insulin 1, Dizziness 3 M Burning Tingling Insulin 2, M Burning Painful Oral 2, F Shooting Painful Insulin 1, M Aching Painful Insulin 2, Somnolence 7 F Shooting Painful Oral 1, M Cramping Painful Oral 1, F Burning Tingling Oral 1, F Cramping Painful Oral 2, F Stabbing Tingling Oral 1, F Cramping Tingling Insulin 1, Ataxia 13 M Cramping Tingling Oral 2, Pain/ d as follows: 0, no /; 1, mild /; 2, moderate /; 3, severe /; 4, excruciating /.
4 Vol. 20 No. 4 October 2000 GBP vs. AMI in Painful Diabetic Neuropathy 283 Patient no. Gender Age Diabetes Pain (months) Type of Type of Table 2 Data for AMI-Treated Patients Antidiabetic therapy Maximum dose (mg/day) Adverse events 1 F Shooting Painful Oral Somnolence, dry mouth 2 M Burning Tingling Insulin Somnolence, dry mouth, constipation 3 M Burning Tingling Insulin Dizziness, somnolence, constipation 4 F Shooting Painful Oral Constipation, somnolence, orthostatic hypotension 5 F Cramping Tingling Insulin Somnolence, dry mouth 6 M Burning Painful Insulin Dry mouth, weight increase 7 F Shooting Tingling Oral F Burning Tingling Oral Dizziness 9 M Shooting Painful Oral Dizziness, visual disturbances 10 F Cramping Tingling Oral Dizziness 11 F Cramping Tingling Oral Somnolence, dizziness, constipation, weight increase 12 M Cramping Painful Insulin Dry mouth, dysuria Pain/ d as follows: 0, no /; 1, mild /; 2, moderate /; 3, severe /; 4, excruciating /.
5 284 Dallocchio et al. Vol. 20 No. 4 October 2000 Group Table 3 and End-Point Pain Scores for Gabapentin and Amitriptyline Variable Change in P value vs. baseline P value between treatments Gabapentin Mean Standard deviation Amitriptyline Mean Standard deviation males) received AMI at the mean dose of mg/day. The data of each GBP-treated patient and AMI-treated patient are reported in Tables 1 and 2. The two groups were comparable at baseline for age (mean: 71 7 years in the GBP group; 71 6 years in the AMI group), of diabetes (mean: 12 4 years for GBP; 9 7 years for AMI), (mean: for GBP; for AMI), and (mean: for GBP; for AMI). However, of was significantly longer in the GBP group (mean: months vs months for AMI) (Mann- Whitney U-test, P 0.026). Pain Score Pain s are shown in Tables 1 3. In the GBP and AMI groups, the mean final s were 1.0 (1.9 lower than baseline value, Wilcoxon test, P 0.01) and 1.5 (1.3 below baseline, Wilcoxon test, P 0.01), respectively. The efficacy of GBP in reducing was significantly superior in comparison with AMI (Mann-Whitney U-test, P 0.026). The goal of therapy was to achieve a intensity of 1 or less. In seven GBP-treated patients (nos. 4, 5, 7, 8, 9, 12, and 13) and eight AMI-treated patients (nos. 2, 5, 6, 7, 8, 9, 10, and 11), the final of 1 was attained and considered satisfactory by patients, who refused any further increase in the dose. In three GBP-treated patients (nos. 6, 10, and 11), a of 0 was attained, while this goal could not be achieved in any AMI-treated patients. Three GBP-treated patients (nos. 1, 2, and 3) and four AMI-treated patients (nos.1, 3, 4, and 12) did not achieve the goal of reducing to 1 or 0. In the GBP-treated patient no. 1, the maximum dosage of 2,400 mg/day was reached (notably without side effects, but a further increase in the dosage was not allowed by the protocol), while the dosage was not increased up to the maximum in the GBP-treated patients nos. 2 and 3, because of the occurrence of intolerable dizziness. The occurrence of side effects (somnolence, dry mouth, dizziness, constipation, orthostatic hypotension, and dysuria) prevented further dose increases in all four AMI patients (nos. 1, 3, 4, and 12) who could not attain the therapy goal. Paresthesia Score Paresthesia s are shown in Tables 1, 2, and 4. In the GBP group, mean final was 1.2 (1.8 below baseline value, Wilcoxon test, P 0.01). This was 1.6 in the AMI group (0.9 below baseline, Wilcoxon test, P 0.01). Again, there was a significant difference between improvements (Mann-Whitney, P 0.004). The efficacy of GBP in reducing was markedly greater than AMI: nine GBPtreated patients achieved a of 1 or less (two reached 0), in comparison with four AMItreated patients (none reached 0). Group Table 4 and End-Point Paresthesia Scores for Gabapentin and Amitriptyline Variable Change in P value vs. baseline P value between treatments Gabapentin Mean Standard deviation Amitriptyline Mean Standard deviation
6 Vol. 20 No. 4 October 2000 GBP vs. AMI in Painful Diabetic Neuropathy 285 Side Effects Four patients in the GBP group reported side effects (two dizziness, one somnolence, and one ataxia) compared with 11 patients in the AMI group (somnolence, dizziness, and dry mouth were the most common). The difference in frequency of side effects between the two therapies was statistically significant (Fisher s exact test: P 0.003). use of randomization. Moreover, the trial was performed in 1997, when GBP had been available in Italy for the treatment of epilepsy just for 1 year and neurologists had not yet used the new drug for. Therefore, neither physicians nor patients had biases toward which drug might be better. Regardless, the results from this study are preliminary and need to be confirmed in a larger, double-blind trial. Discussion In this open-label comparison between GBP and AMI in the treatment of patients with ful diabetic neuropathy, both drugs were shown to be effective, but GBP was statistically better than AMI in relieving and. In addition, AMI caused statistically more side effects than GBP. Side effects of AMI, such as dry mouth and orthostatic hypotension, are particularly poorly tolerated by elderly patients, who often would rather accept a residual than continue taking AMI. In a controlled trial of GBP in postherpetic neuralgia, a disorder also characterized by an elderly patient population, the reported incidence of side effects was higher than in the present study. 13 However, this could be explained by the fact that all patients dosages were titrated up to 3,600 mg/day in that study, compared with the mean dose of less than 1,800 mg/day in this trial. TCAs are considered as a first-line therapy for ful diabetic neuropathy. Among TCAs, AMI is the most effective, even if probably the least-tolerated one. Therefore, the results of the present study should not be generalized to all TCAs, because it cannot be excluded that choosing a TCA with less anticholinergic side effects, such as imipramine, would result in a substantial equivalence of the two treatments. Nonetheless, clinical experience, along with the results of the placebo-controlled trial, 1 suggest that GBP is a well-tolerated treatment for ful diabetic neuropathy, and perhaps it should be considered as a first-line therapy for this condition. Potential advantages of GBP over a TCA include its apparently better tolerability, safety profile, and lack of drug interactions. The results of this trial cannot be considered conclusive because of the small sample size and lack of blinding. However, possible biases due to lack of blinding were reduced by the References 1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, et al. Gabapentin for the symptomatic treatment of ful neuropathy in patients with diabetes mellitus, a randomized controlled study. JAMA 1998;280: Low PA and Dotson RM. Symptomatic treatment of ful neuropathy. JAMA 1998;280: McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, et al. A systematic review of antidepressants in neuropathic. Pain 1996;68: Young RJ, Clarke BP. Pain relief in diabetic neuropathy: The effectiveness of imipramine and related drugs. Diabetic Med 1985;2: Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, et al. Amitriptyline relieves diabetic neuropathy in patients with normal and depressed mood. Neurology 1987;37: Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic states. Drugs & Aging 1996;8: Biesbroeck R, Bril V, Hollander P, Kabadi U, Schwartz S, et al. A double-blind comparison of topical capsaicin and oral amitriptyline in ful diabetic neuropathy. Adv Ther 1995;12(2): Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, et al. Efficacy of desipramine in ful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45: Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of ful diabetic neuropathy. JAMA 1984;251: Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back. Pain 1998;76: Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA. Utilization patterns of tricyclic antidepressants in a multidisciplinary clinic: A survey. Clin J Pain 1997;13: Joss JD. Tricyclics antidepressant use in diabetic neuropathy. Ann Pharmacother 1999;33(9): Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia, a randomized controlled study. JAMA 1998;280:
GABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act
GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin
More informationDiagnosis and Treatment of Postherpetic Neuralgia
J KMA Special Issue Diagnosis and Treatment of Postherpetic Neuralgia Myung Ha Yoon, MD Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School E mail : mhyoon@jnu.ac.kr
More informationDivalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study
Q J Med 25; 98:29 34 doi:1.193/qjmed/hci5 Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study D.K. KOCHAR, P. GARG, R.A. BUMB, S.K. KOCHAR,
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationControlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuropathic Pain
80 Chin J Cancer Res 22(1):80-86, 2010 www.springerlink.com Original Article Controlled-Release Oxycodone Alone or Combined with Gabapentin for Management of Malignant Neuropathic Pain Xiao-mei Li 1*,
More informationApplication for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation
Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation Below is the form you need to fill out. NAME Dianne Vicary Health Hawke s Bay DATE JUNE 2012 TITLE OF ACTIVITY
More informationCONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012
CONCORD INTERNAL MEDICINE Peripheral Neuropathy Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD April 22, 2012 The information contained in this protocol should never
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationDiabetic Peripheral Neuropathic Pain: Evaluating Treatment Options
Diabetic Peripheral Neuropathic Pain: Evaluating Treatment Options Ramon L. Cuevas-Trisan, MD Disclosures Speakers Bureau/Honoraria: Allergan, Ipsen 1 Learning Objectives Discuss practical approaches to
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationTITLE: Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness
TITLE: Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness DATE: 22 January 2016 CONTEXT AND POLICY ISSUES Neuropathic pain can be severe and debilitating and results
More informationUnderstanding and Treating Post- Herpetic Neuralgia (PHN)
Understanding and Treating Post- Herpetic Neuralgia (PHN) Mary Lynn McPherson, Pharm.D., BCPS Professor University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu This program has been supported
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationA Phase II Study to Establish the Efficacy and Toxicity of Sodium Valproate in Patients With Cancer-Related Neuropathic Pain
204 Journal of Pain and Symptom Management Vol. 21 No. 3 March 2001 Original Article A Phase II Study to Establish the Efficacy and Toxicity of Sodium Valproate in Patients With Cancer-Related Neuropathic
More informationControlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy
Pain 105 (2003) 71 78 www.elsevier.com/locate/pain Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy C. Peter N. Watson a, *, Dwight Moulin
More informationPharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases
PAIN MEDICINE Volume 5 Number S1 2004 Pharmacologic Management Part 1: Better-Studied Neuropathic Pain Diseases Misha-Miroslav Backonja, MD,* Jordi Serra, MD *University of Wisconsin Hospital and Clinics,
More informationSetting The setting was primary and secondary care. The economic study was carried out in Canada.
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Tarride J E, Gordon A, Vera-Llonch
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 03 Nov 2018 09:24:50 GMT) CTRI Number Last Modified On 10/06/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationMedizinische Klinik 1 und Klinische Chemie, University Hospital, Heidelberg, Germany *PMH and MM contributed equally.
PAIN MEDICINE Volume Number 28 External Electric Muscle Stimulation Improves Burning Sensations and Sleeping Disturbances in Patients with Type 2 Diabetes and Symptomatic Neuropathy Per M. Humpert, MD,
More informationUnmet Needs in the Management of Neuropathic Pain
S12 Journal of Pain and Symptom Management Vol. 25 No. 5S May 2003 Neuropathic Pain: From Mechanisms to Treatment Strategies Unmet Needs in the Management of Neuropathic Pain Norman Harden, MD and Mitchell
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Stroke Rehabilitation Evidence Tables Rehabilitation to Improve Central Pain
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Rehabilitation to Improve Central Pain Hebert, D, Teasell, R (Writing Group Chairs) on Behalf of the STROKE REHABILITATION Writing Group 2015 December 2015
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: HIM.PA.64 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationThe clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines
The clinical landscape of painful diabetic neuropathy therapy: perspectives for clinicians from clinical practice guidelines Clin. Invest. (2012) 2(5), 483 489 Painful diabetic neuropathy (PDN) is highly
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationTRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of
More informationGabapentin in Phantom Limb Pain Management in Children and Young Adults: Report of Seven Cases
78 Journal of Pain and Symptom Management Vol. 21 No. 1 January 2001 Clinical Note Gabapentin in Phantom Limb Pain Management in Children and Young Adults: Report of Seven Cases Lynn M. Rusy, MD, Todd
More informationTable A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents
Table A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents Food and Drug Administration. Guidance for Industry Adverse Reactions
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationNortriptyline vs amitriptyline in elderly
Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are
More informationCapsaicin cutaneous patch
New Medicines Profile August 2010 Issue. 10/03 cutaneous patch Concise evaluated information to support the managed entry of new medicines in the NHS Summary cutaneous patch (Qutenza ) is licensed for
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationSAFETY OF PREGABALIN, GABAPENTIN AND AMITRIPTYLINE IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY
85 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(3): May-June 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES
More informationExecutive Summary Pregabalin (Lyrica by Pfizer) Formulary Review
Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review Lyrica (pregabalin) is a new prescription medication indicated for use in painful diabetic peripheral neuropathy (DPN), post-herpetic neuralgia,
More informationDRAFT. Drugs for Neuropathic Pain
DRAFT Drugs for Neuropathic Pain March 2008 Produced by: The Health Resources Commission Office for Oregon Health Policy & Research 1225 Ferry Street SE Salem, OR 97301 Phone: 503.373.1629 Health Resources
More informationApproaches to Managing Neuropathic Pain. Nov 7, 2017
1 Approaches to Managing Neuropathic Pain Nov 7, 2017 3 Learning objectives Review the current Canadian Guidelines on Neuropathic Pain Review the diagnosis and options available for the management of Neuropathic
More informationPart 2: Pain and Symptom Management Depression
Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,
More information1. Developed: June Revised: November 2017; September 2015; December 2013; January 2012; December 2011; April 2010; August 2006.
Texas Vendor Drug Program Drug Use Criteria: Gabapentin Publication History 1. Developed: June 2006 2. Revised: November 2017; September 2015; December 2013; January 2012; December 2011; April 2010; August
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders
More informationNon-opioid and adjuvant pain management
Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lidoderm, ZTlido) Reference Number: CP.PMN.08 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end
More informationPain is one of the most frequent clinical problems
Easing the Ouch: Relieving Short-Term Pain By Brian Goldman, MD, MCFP(EM) As presented at the Family Medicine Forum, Montreal, Quebec (November 8, 2002) Pain is one of the most frequent clinical problems
More informationGabapentin to treat neuropathy
Gabapentin to treat neuropathy Search Gabapentin (brand names Neurontin, Gralise, andothers) is a prescription drug used to treat seizure disorders and nerve damage from shingles. Off label uses (non-fda.
More informationTrial of Amitriptyline for Relief of Pain in Amputees: Results of a Randomized Controlled Study
ARTICLES Trial of Amitriptyline for Relief of Pain in Amputees: Results of a Randomized Controlled Study Lawrence R. Robinson, MD, Joseph M. Czerniecki, MD, Dawn M. Ehde, PhD, W. Thomas Edwards, MD, PhD,
More informationPain Signaling Neuropathic Pain Distinctly different from nociceptive pain Sustained by abnormal processing of sensory input by the peripheral or cent
Objectives Pharmacologic Management of Neuropathic Pain Joseph R. Ineck, Pharm.D.,., CPE Pharmacist: St. Luke s Health System At the conclusion of this presentation, pharmacists will be able to: 1. Differentiate
More informationIs Topical Clonazepam More Effective Than Oral Clonazepam in Treatment of Burning Mouth Syndrome (BMS)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Topical Clonazepam More Effective
More informationEquivalency of tricyclic antidepressants in open-label neuropathic pain study
Acta Neurol Scand DOI: 10.1111/ane.12169 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Equivalency of tricyclic antidepressants in open-label neuropathic
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Phase of Drug Development. Study Start/End Dates
Sponsor Novartis Generic drug name SAB378 [Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone] Trial indication(s) Postherpetic neuralgia (PHN) Protocol number CSAB378A2201 Protocol title A multicenter,
More informationPractice Name. Audit Undertaken By and Job Title. Date of Audit
Pregabalin Audit Template This template can be used to document the Pregabalin audit undertaken by practices as part of the Incentive Scheme. It has been produced to provide practices with a guide but
More informationEfficacy of Gabapentin in Neuropathic Pain: A Study at Nobel Medical College and Teaching Hospital, Nepal
American Journal of Public Health Research, 2015, Vol. 3, No. 5A, 57-63 Available online at http://pubs.sciepub.com/ajphr/3/5a/13 Science and Education Publishing DOI:10.12691/ajphr-3-5A-13 Efficacy of
More informationRESEARCH. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review
Effects of s for symptoms of painful diabetic neuropathy: systematic review Man-chun Wong, pain management nurse, 1 Joanne W Y Chung, professor, 2 Thomas K S Wong, chair professor 2 1 Nursing Services
More informationPain Associated with Diabetic Peripheral Neuropathy
CONTINUING EDUCATION CREDIT Pain Associated with Diabetic Peripheral Neuropathy A Review of Available Treatments Erin L. St. Onge, PharmD, and Shannon A. Miller, PharmD Educational Objectives After reviewing
More informationADJUVANT PAIN MANAGEMENT
ADJUVANT PAIN MANAGEMENT Bruce H. Chamberlain, MD FACP FAAHPM Palliative Consulting Orem, UT AAHPM Intensive Board Review Course Using Adjuvant Treatments for Chronic Pain Bruce H. Chamberlain, MD FACP
More informationPain Management in the
Pain Management in the Elderly Meri Hix, PharmD, CGP, BCPS Associate Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy No conflicts of interest to declare Objectives Discuss
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationWhich TCAs and what dosing is recommended for the different types of chronic non-cancer pain as recommended in the chart for key message 1?
Which TCAs and what dosing is recommended for the different types of chronic non-cancer pain as recommended in the chart for key message 1? Tricyclic antidepressants (TCAs) are agents approved for the
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationNeuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings
DRAFT FOR COSULTATIO 0 europathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings Full guideline Draft for consultation, October 00 This guideline was developed
More information1/21/14. Barriers to Assessment and Management of Chemotherapy- Induced Peripheral Neuropathy. Conflicts of Interest. Learning Objective
Barriers to Assessment and Management of Chemotherapy- Induced Peripheral Neuropathy Connie Visovsky, PhD, RN, ACNP-BC Associate Dean University of South Florida College of Nursing Conflicts of Interest
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationNational Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationBurning Mouth Syndrome. Nurdiana, drg., Sp.PM
Burning Mouth Syndrome Nurdiana, drg., Sp.PM DEFINITION Burning Mouth Syndrome (BMS) oral burning tongue/other mucous membranes no detectable cause, anatomic pathways, mucosal lesions, neurologic disorders
More informationHTA. technology overview
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé technology overview HTA Issue 49 January 2009 Overview of Anticonvulsants, Serotonin-Norepinephrine
More informationNortriptyline for neuropathic pain in adults (Review)
Derry S, Wiffen PJ, Aldington D, Moore RA This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 1 http://www.thecochranelibrary.com
More informationSince the earliest descriptions of pain related to injury of the nervous system, it has been
Continuing Education Column Diagnosis and Treatment of Neuropathic Pain Minn Yang Ki, MD Department of Neurology, Hallym University College of Medicine E - mail : yangki2@unitel.co.kr Seung Min Kim, MD
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationOther classical forms of neuropathic pain include diabetic peripheral neuropathy, trigeminal neuralgia and postherpetic
Guideline Name: Neuropathic Pain Neuropathic pain is defined by the International Association for the Study of Pain, Neuropathic Special Interest group as pain arising as a direct consequence of a lesion
More informationNeuropathic Pain. Griffith Research Online. Author. Published. Journal Title. Copyright Statement. Downloaded from. Link to published version
Griffith Research Online https://research-repository.griffith.edu.au Neuropathic Pain Author Hall, Tony Published 2010 Journal Title Australian Journal of Pharmacy Copyright Statement Copyright 2010 Australian
More informationPostherpetic neuralgia *
Section 1 Chapter 1 Neurological Disorders Postherpetic neuralgia * Alan David Kaye and Charles E. Argoff Case study A 78-year-old male with a history of postherpetic neuralgia (PHN) as well as hypertension
More informationREFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Lidoderm/Versatis in the 7MM neuropathic
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationLidoderm (lidocaine 5% patch)
Lidoderm (lidocaine 5% patch) Policy Number: 5.01.562 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Lidoderm
More informationREFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Qutenza in the 7MM neuropathic pain markets during
More informationThe World Health Organization (WHO) has described diabetes mellitus as Metabolic
1.1. Background The World Health Organization (WHO) has described diabetes mellitus as Metabolic disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrate,
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationPalliative Prescribing - Pain
Palliative Prescribing - Pain LAURA BARNFIELD 21/2/17 Aims To understand the classes of painkillers available in palliative care To gain confidence in counselling regarding opiates To gain confidence prescribing
More informationPain CONCERN. Medicines for long-term pain. Antidepressants
Pain CONCERN Medicines for long-term pain Antidepressants Many people living with long-term pain (also known as chronic or persistent pain) are worried about using medicines like antidepressants. They
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationOptimizing Non-Opioid Therapy for Chronic Pain
Optimizing Non-Opioid Therapy for Chronic Pain Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means
More informationPainful Diabetic Neuropathy Effective Management. Ketan Dhatariya Consultant in Diabetes NNUH
Painful Diabetic Neuropathy Effective Management Ketan Dhatariya Consultant in Diabetes NNUH Neuropathic Pain Prevalence varies between 10 and 90% depending on classification Accounts for 50-75% of non-traumatic
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More information7/13/16 DISCLOSURE OBJECTIVES THINKING OUTSIDE THE BOX: NON-OPIATE PAIN MEDICATIONS AND CUSTOMIZED MEDICATION OPTIONS
THINKING OUTSIDE THE BOX: NON-OPIATE PAIN MEDICATIONS AND CUSTOMIZED MEDICATION OPTIONS Dawn Ipsen, PharmD, Owner Kusler s Compounding Pharmacy Snohomish, WA dawn@kuslers.com 360-568-1297 AANP Annual Convention
More informationThe Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI
More informationLOYOLA COLLEGE (AUTONOMOUS), CHENNAI
LOYOLA COLLEGE (AUTONOMOUS), CHENNAI 600 034 M.Sc. DEGREE EXAMINATION STATISTICS THIRD SEMESTER NOVEMBER 2015 ST 3958 - NON PARAMETRIC INFERENCE Date : 11/11/2015 Dept. No. Max. : 100 Marks Time : 09:00-12:00
More informationObjectives. VZV breaks out of the nerve cell body and travels down the nerve axons causing an infection of the skin in the region of the nerve
Deena B. Hollingsworth MSN, FNP-BC ENT Specialists of Northern Virginia Falls Church, Virginia Objectives Describe common signs and symptoms of herpes zoster Discuss the pathophysiology and diagnosis of
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Drug Therapy for Neuropathic Pain in the Medically Ill Russell K. Portenoy, MD Executive Director, MJHS Institute for Innovation in Palliative Care Chief Medical Officer,
More information